Literature DB >> 12062540

Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products.

Sudhish Chandra1, A Groener, F Feldman.   

Abstract

An issue of great importance and continuing concern with regard to all products derived from human plasma is their safety from potential contaminants in the source material from which they are purified. Since viral contaminants are a major safety consideration with these products, a number of different methods, including dry heating, vapor heating, filtration and nanofiltration, ultraviolet and gamma irradiation, pasteurization, solvent/detergent (S/D) treatment, sodium thiocyanate treatment, and chromatography (immunoaffinity, metal chelation, affinity, and ion exchange), have been developed to remove or inactivate potentially contaminating viruses. Pasteurization and S/D treatment have emerged as the dominant viral inactivation methods. Results summarized in this review demonstrate that pasteurization is the broadest and most rigorous currently available method for removal of potential viral contaminants from plasma-derived products. S/D treatment requires control over a large number of manufacturing parameters and has no ability to inactivate nonlipid-enveloped viruses. Pasteurization requires control over only a small number of manufacturing variables, is easily monitored, and remains effective even if deviations are encountered from specified protein and stabilizer concentrations and temperature. In addition, pasteurization is effective against a wide range of lipid- and nonlipid-enveloped viruses.

Entities:  

Mesh:

Year:  2002        PMID: 12062540     DOI: 10.1016/s0049-3848(02)00044-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  11 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 2.  Advancement in bioprocess technology: parallels between microbial natural products and cell culture biologics.

Authors:  Arpan A Bandyopadhyay; Anurag Khetan; Li-Hong Malmberg; Weichang Zhou; Wei-Shou Hu
Journal:  J Ind Microbiol Biotechnol       Date:  2017-02-09       Impact factor: 3.346

Review 3.  C1 inhibitor deficiency: consensus document.

Authors:  M M Gompels; R J Lock; M Abinun; C A Bethune; G Davies; C Grattan; A C Fay; H J Longhurst; L Morrison; A Price; M Price; D Watters
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

4.  Loss of fibrinogen in zebrafish results in an asymptomatic embryonic hemostatic defect and synthetic lethality with thrombocytopenia.

Authors:  Zhilian Hu; Kari I Lavik; Yang Liu; Andy H Vo; Catherine E Richter; Jorge Di Paola; Jordan A Shavit
Journal:  J Thromb Haemost       Date:  2019-02-25       Impact factor: 5.824

Review 5.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 6.  Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Authors:  Kang Cai; Todd M Gierman; JoAnn Hotta; Christopher J Stenland; Douglas C Lee; Dominique Y Pifat; Steve R Petteway
Journal:  BioDrugs       Date:  2005       Impact factor: 5.807

Review 7.  Pathogen inactivation techniques.

Authors:  J P R Pelletier; S Transue; E L Snyder
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

Review 8.  Treatment of congenital fibrinogen deficiency: overview and recent findings.

Authors:  Konstantinos Tziomalos; Sofia Vakalopoulou; Vassilios Perifanis; Vassilia Garipidou
Journal:  Vasc Health Risk Manag       Date:  2009-10-12

9.  Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A.

Authors:  Steven Pipe
Journal:  Biologics       Date:  2009-07-13

10.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.